Schneier Franklin R, Belzer Kenneth D, Kishon Ronit, Amsel Lawrence, Simpson Helen Blair
Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, NY 10032, USA.
J Nerv Ment Dis. 2010 Jun;198(6):458-61. doi: 10.1097/NMD.0b013e3181da4d77.
Cognitive behavioral therapy (CBT) and pharmacotherapy are each efficacious for generalized anxiety disorder (GAD). It is not known, however, whether GAD partial and nonresponders to one treatment modality benefit from the other. This study explored acceptability and efficacy of escitalopram for persons with persistent GAD symptoms after a course of CBT. Twenty-four patients with GAD were treated with CBT and 15 completed at least 12 sessions. Eight completers continued to have clinically significant symptoms and were offered 12 weeks of treatment with escitalopram, and 7 started escitalopram treatment. During CBT, patients evidenced significant improvement in GAD, depression, and quality of life. During escitalopram treatment, patients evidenced trends toward further improvement in GAD, depression, and quality of life. Escitalopram phase completers had initially reported low-to-moderate preferences for medication treatment. Escitalopram may benefit GAD patients with clinically significant symptoms after CBT and merits further study under controlled conditions in a larger sample.
认知行为疗法(CBT)和药物疗法对广泛性焦虑症(GAD)均有效。然而,尚不清楚对一种治疗方式部分应答或无应答的GAD患者是否能从另一种治疗方式中获益。本研究探讨了艾司西酞普兰对经过一个疗程CBT后仍有持续性GAD症状患者的可接受性和疗效。24例GAD患者接受了CBT治疗,15例完成了至少12次治疗。8例完成治疗者仍有具有临床意义的症状,被给予12周的艾司西酞普兰治疗,7例开始了艾司西酞普兰治疗。在CBT治疗期间,患者的GAD、抑郁和生活质量有显著改善。在艾司西酞普兰治疗期间,患者的GAD、抑郁和生活质量有进一步改善的趋势。完成艾司西酞普兰治疗阶段的患者最初报告对药物治疗的偏好为低到中度。艾司西酞普兰可能使经过CBT后仍有具有临床意义症状的GAD患者获益,值得在更大样本的对照条件下进行进一步研究。